Mirum Pharmaceuticals Says LIVMARLI Receives FDA Approval For Treatment Of Cholestatic Pruritus In Patients With Progressive Familial Intrahepatic Cholestasis
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Mirum Pharmaceuticals' LIVMARLI for the treatment of cholestatic pruritus in patients with PFIC aged five and older. Mirum also plans to expand the label for younger patients later this year with a new formulation.
March 13, 2024 | 10:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients aged five and older, with plans for label expansion.
FDA approval of a drug significantly boosts a pharmaceutical company's market potential and investor confidence. The approval of LIVMARLI for a specific patient group and the potential label expansion for younger patients later this year could lead to increased sales and market penetration for Mirum Pharmaceuticals. This regulatory milestone is a positive development for the company, likely leading to a short-term positive impact on its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100